FDA Brief

Warning letters Drugs

FDA warning letter to

Fei Fah Medical Manufacturing Pte. Ltd.

High riskIssued Jan 30, 2023Posted Jan 31, 2023Center for Drug Evaluation and Research | CDER

FDA warned Fei Fah Medical Manufacturing over inadequate stability data, unvalidated test methods, and supplier testing failures for over-the-counter drugs.

What happened

FDA reviewed records Fei Fah submitted after FDA's May 18, 2021 request for records and the firm's March 28, 2022 response. FDA found inadequate stability data to support expiration dates, unvalidated assay methods and missing impurity specifications, and failure to test incoming components or qualify suppliers. The letter also notes similar stability findings in March 2013 and December 2015 inspections.

What FDA found

  1. The firm lacked adequate stability data to support expiration dates and did not use methods that can detect impurities or degradants.

    21 CFR 211.166(a)
  2. The firm did not establish suitable laboratory controls, validate its assay test method, or set release specifications for impurities.

    21 CFR 211.160(b)
  3. The firm did not test each incoming component lot for identity and did not qualify suppliers or verify their certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)

What FDA wants

FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with corrective action plans, independent assessments, test results, and any reason for delay.

Who should pay attention

  • brands that buy OTC drugs from this contract manufacturer
  • U.S. distributors and retailers selling its drug products
  • companies relying on supplier certificates of analysis for incoming components

This is a summary. Read the original letter on fda.gov.

Fei Fah Medical Manufacturing Pte. Ltd.'s FDA history

Recalls in the last 12 months

Nov 4 Class II Fei Fah Medical Manufacturing Pte. Ltd.
Drug
ULTRA STRENTGH, ELECTRIC MIDICATED BALM (menthol 16% and methyl salicylate 32%) packaged in a) Net 2.45 oz (70g) (NDC 63299-001-01) and b) 10g (NDC 63299-001-02), Manufactured by Fei Fah Medical Mfg Pte Ltd, Singapore, U…
CGMP Deviations

Full company page

Similar letters to other companies

  1. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  2. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  3. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  4. R3 Medical Companies

    FDA cites R3 Medical affiliates for selling unapproved umbilical cord and exosome biologics without licenses and with serious manufacturing violations.

    High risk